PC
EW icon

PointState Capital’s Edwards Lifesciences EW Stock Holding History

PointState Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-65,000
Closed -$7.36M – 139
2021
Q3 		$7.36M Sell
65,000
-5,000
-7% -$571K 0.12% 95
2021
Q2 		$7.25M Buy
+70,000
New +$6.6M 0.13% 85
2015
Q3 		– Sell
-600,000
Closed -$14.2M – 108
2015
Q2 		$14.2M Buy
+600,000
New +$13.5M 0.17% 82

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PointState Capital's EW Position: Q4 2021 in Review

PointState Capital sold out of Edwards Lifesciences (EW) in Q4 2021, closing a stake of 65,000 shares — an estimated $7.36M sold.

PointState Capital first reported a position in EW in Q2 2015 and held it in 3 quarters. The position peaked at $14.2M in Q2 2015. 1,319 funds tracked by Wall St. Rank hold EW as of Q4 2021.

  • PointState Capital reported no remaining Edwards Lifesciences position as of Q4 2021 after selling out during the quarter.
  • PointState Capital sold 65,000 Edwards Lifesciences shares in Q4 2021, an estimated $7.36M.
  • PointState Capital first reported a position in Edwards Lifesciences in Q2 2015 and held it in 3 quarters.
  • PointState Capital's Edwards Lifesciences position peaked at $14.2M in Q2 2015.
  • 1,319 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on PointState Capital's 13F filing for Q4 2021, filed 11 Feb 2022.